Pharmarise Holdings Corporation
Simbolis: 2796.T
JPX
659
JPYRinkos kaina šiandien
24.8104
P/E santykis
-0.9523
PEG koeficientas
7.41B
MRK kapitalizacija
- 0.02%
DIV pajamingumas
Pharmarise Holdings Corporation (2796-T) Finansinės ataskaitos
Balansas
common:word.in-mln USD Growth | TTM | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | |||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
balance-sheet.row.cash-and-short-term-investments | 0 | 4742 | 3991 | 4604 | ||||||||||||||||
balance-sheet.row.short-term-investments | 0 | -1926 | -2079 | -2427 | ||||||||||||||||
balance-sheet.row.net-receivables | 0 | 605 | 479 | 926 | ||||||||||||||||
balance-sheet.row.inventory | 0 | 2290 | 2302 | 2587 | ||||||||||||||||
balance-sheet.row.other-current-assets | 0 | 317 | 315 | 260 | ||||||||||||||||
balance-sheet.row.total-current-assets | 0 | 11372 | 10878 | 10546 | ||||||||||||||||
balance-sheet.row.property-plant-equipment-net | 0 | 6007 | 6355 | 6432 | ||||||||||||||||
balance-sheet.row.goodwill | 0 | 2748 | 3220 | 4025 | ||||||||||||||||
balance-sheet.row.intangible-assets | 0 | 501 | 408 | 438 | ||||||||||||||||
balance-sheet.row.goodwill-and-intangible-assets | 0 | 3249 | 3628 | 4463 | ||||||||||||||||
balance-sheet.row.long-term-investments | 0 | 2008 | 2139 | 2488 | ||||||||||||||||
balance-sheet.row.tax-assets | 0 | 778 | 741 | 786 | ||||||||||||||||
balance-sheet.row.other-non-current-assets | 0 | 0 | 0 | 4 | ||||||||||||||||
balance-sheet.row.total-non-current-assets | 0 | 12042 | 12863 | 14173 | ||||||||||||||||
balance-sheet.row.other-assets | 0 | 7 | 5 | 5 | ||||||||||||||||
balance-sheet.row.total-assets | 0 | 23421 | 23746 | 24724 | ||||||||||||||||
balance-sheet.row.account-payables | 0 | 4252 | 4109 | 4609 | ||||||||||||||||
balance-sheet.row.short-term-debt | 0 | 3677 | 2490 | 2819 | ||||||||||||||||
balance-sheet.row.tax-payables | 0 | 333 | 429 | 573 | ||||||||||||||||
balance-sheet.row.long-term-debt-total | 0 | 5461 | 7422 | 7878 | ||||||||||||||||
Deferred Revenue Non Current | 0 | -42 | -31 | 0 | ||||||||||||||||
balance-sheet.row.deferred-tax-liabilities-non-current | 0 | - | - | - | ||||||||||||||||
balance-sheet.row.other-current-liab | 0 | 747 | 691 | 645 | ||||||||||||||||
balance-sheet.row.total-non-current-liabilities | 0 | 6600 | 8571 | 9001 | ||||||||||||||||
balance-sheet.row.other-liabilities | 0 | 0 | 0 | 0 | ||||||||||||||||
balance-sheet.row.capital-lease-obligations | 0 | 432 | 551 | 700 | ||||||||||||||||
balance-sheet.row.total-liab | 0 | 16435 | 17048 | 18393 | ||||||||||||||||
balance-sheet.row.preferred-stock | 0 | 0 | 0 | 0 | ||||||||||||||||
balance-sheet.row.common-stock | 0 | 1298 | 1274 | 1251 | ||||||||||||||||
balance-sheet.row.retained-earnings | 0 | 4014 | 3811 | 3494 | ||||||||||||||||
balance-sheet.row.accumulated-other-comprehensive-income-loss | 0 | 226 | 203 | 208 | ||||||||||||||||
balance-sheet.row.other-total-stockholders-equity | 0 | 1343 | 1319 | 1268 | ||||||||||||||||
balance-sheet.row.total-stockholders-equity | 0 | 6881 | 6607 | 6221 | ||||||||||||||||
balance-sheet.row.total-liabilities-and-stockholders-equity | 0 | 23421 | 23746 | 24724 | ||||||||||||||||
balance-sheet.row.minority-interest | 0 | 105 | 91 | 110 | ||||||||||||||||
balance-sheet.row.total-equity | 0 | 6986 | 6698 | 6331 | ||||||||||||||||
balance-sheet.row.total-liabilities-and-total-equity | 0 | - | - | - | ||||||||||||||||
Total Investments | 0 | 82 | 60 | 61 | ||||||||||||||||
balance-sheet.row.total-debt | 0 | 9138 | 9912 | 10697 | ||||||||||||||||
balance-sheet.row.net-debt | 0 | 4396 | 5921 | 6093 |
Pinigų srautų ataskaita
common:word.in-mln USD Growth | TTM | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | |||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
cash-flows.row.net-income | 0 | 1049 | 1322 | 1202 | ||||||||||||||||
cash-flows.row.depreciation-and-amortization | 0 | 1224 | 1308 | 1344 | ||||||||||||||||
cash-flows.row.deferred-income-tax | 0 | 0 | 0 | 0 | ||||||||||||||||
cash-flows.row.stock-based-compensation | 0 | 0 | 0 | 0 | ||||||||||||||||
cash-flows.row.change-in-working-capital | 0 | 513 | -1465 | -139 | ||||||||||||||||
cash-flows.row.account-receivables | 0 | 482 | -1319 | 365 | ||||||||||||||||
cash-flows.row.inventory | 0 | 68 | 286 | 56 | ||||||||||||||||
cash-flows.row.account-payables | 0 | 13 | -500 | -582 | ||||||||||||||||
cash-flows.row.other-working-capital | 0 | -50 | 68 | 22 | ||||||||||||||||
cash-flows.row.other-non-cash-items | 0 | -266 | -452 | -462 | ||||||||||||||||
cash-flows.row.net-cash-provided-by-operating-activities | 0 | 0 | 0 | 0 | ||||||||||||||||
cash-flows.row.investments-in-property-plant-an-equipment | 0 | -542 | -466 | -552 | ||||||||||||||||
cash-flows.row.acquisitions-net | 0 | -180 | 2 | -116 | ||||||||||||||||
cash-flows.row.purchases-of-investments | 0 | 0 | -2 | -2 | ||||||||||||||||
cash-flows.row.sales-maturities-of-investments | 0 | 0 | 383 | 12 | ||||||||||||||||
cash-flows.row.other-investing-activites | 0 | 19 | -209 | -418 | ||||||||||||||||
cash-flows.row.net-cash-used-for-investing-activites | 0 | -703 | -292 | -1076 | ||||||||||||||||
cash-flows.row.debt-repayment | 0 | -2419 | -2636 | -2857 | ||||||||||||||||
cash-flows.row.common-stock-issued | 0 | 0 | 1737 | 2199 | ||||||||||||||||
cash-flows.row.common-stock-repurchased | 0 | 0 | -2 | -36 | ||||||||||||||||
cash-flows.row.dividends-paid | 0 | -131 | -131 | -129 | ||||||||||||||||
cash-flows.row.other-financing-activites | 0 | 1478 | -2 | 95 | ||||||||||||||||
cash-flows.row.net-cash-used-provided-by-financing-activities | 0 | -1072 | -1034 | -728 | ||||||||||||||||
cash-flows.row.effect-of-forex-changes-on-cash | 0 | -2 | 0 | -1 | ||||||||||||||||
cash-flows.row.net-change-in-cash | 0 | 743 | -613 | 140 | ||||||||||||||||
cash-flows.row.cash-at-end-of-period | 0 | 4734 | 3991 | 4604 | ||||||||||||||||
cash-flows.row.cash-at-beginning-of-period | 0 | 3991 | 4604 | 4464 | ||||||||||||||||
cash-flows.row.operating-cash-flow | 0 | 2520 | 713 | 1945 | ||||||||||||||||
cash-flows.row.capital-expenditure | 0 | -542 | -466 | -552 | ||||||||||||||||
cash-flows.row.free-cash-flow | 0 | 1978 | 247 | 1393 |
Pajamų ataskaitos eilutė
common:word.in-mln USD Growth | TTM | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | |||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
income-statement-row.row.total-revenue | 0 | 52030 | 51608 | 52324 | ||||||||||||||||
income-statement-row.row.cost-of-revenue | 0 | 43896 | 43491 | 44256 | ||||||||||||||||
income-statement-row.row.gross-profit | 0 | 8134 | 8117 | 8068 | ||||||||||||||||
income-statement-row.row.gross-profit-ratio | 0 | 0 | 0 | 0 | ||||||||||||||||
income-statement-row.row.research-development | 0 | - | - | - | ||||||||||||||||
income-statement-row.row.selling-general-administrative | 0 | - | - | - | ||||||||||||||||
income-statement-row.row.selling-and-marketing-expenses | 0 | - | - | - | ||||||||||||||||
income-statement-row.row.other-expenses | 0 | 32 | -7 | 21 | ||||||||||||||||
income-statement-row.row.operating-expenses | 0 | 6695 | 6596 | 6821 | ||||||||||||||||
income-statement-row.row.cost-and-expenses | 0 | 50591 | 50087 | 51077 | ||||||||||||||||
income-statement-row.row.interest-income | 0 | 1 | 1 | 1 | ||||||||||||||||
income-statement-row.row.interest-expense | 0 | 55 | 65 | 75 | ||||||||||||||||
income-statement-row.row.selling-and-marketing-expenses | 0 | - | - | - | ||||||||||||||||
income-statement-row.row.total-other-income-expensenet | 0 | -390 | -200 | -45 | ||||||||||||||||
income-statement-row.row.ebitda-ratio-caps | 0 | - | - | - | ||||||||||||||||
income-statement-row.row.other-operating-expenses | 0 | 32 | -7 | 21 | ||||||||||||||||
income-statement-row.row.total-operating-expenses | 0 | -390 | -200 | -45 | ||||||||||||||||
income-statement-row.row.interest-expense | 0 | 55 | 65 | 75 | ||||||||||||||||
income-statement-row.row.depreciation-and-amortization | 0 | 1224 | 1308 | 1344 | ||||||||||||||||
income-statement-row.row.ebitda-caps | 0 | - | - | - | ||||||||||||||||
income-statement-row.row.operating-income | 0 | 1438 | 1520 | 1246 | ||||||||||||||||
income-statement-row.row.income-before-tax | 0 | 1049 | 1322 | 1202 | ||||||||||||||||
income-statement-row.row.income-tax-expense | 0 | 702 | 863 | 782 | ||||||||||||||||
income-statement-row.row.net-income | 0 | 333 | 447 | 426 |
Dažnai užduodami klausimai
Kas yra Pharmarise Holdings Corporation (2796.T) bendras turtas?
Pharmarise Holdings Corporation (2796.T) bendras turtas yra 23421000000.000.
Kokios yra įmonės metinės pajamos?
Metinės pajamos yra N/A.
Kokia yra įmonės pelno marža?
Įmonės pelno marža yra 0.156.
Koks yra įmonės laisvųjų pinigų srautas?
Laisvųjų pinigų srautas yra 152.963.
Kokia yra įmonės grynojo pelno marža?
Grynojo pelno marža yra 0.006.
Kokios yra bendros įmonės pajamos?
Bendrosios pajamos yra 0.026.
Kas yra Pharmarise Holdings Corporation (2796.T) grynasis pelnas (grynosios pajamos)?
Grynasis pelnas (grynosios pajamos) yra 333000000.000.
Kokia yra bendra įmonės skola?
Bendra skola yra 9138000000.000.
Koks yra veiklos sąnaudų skaičius?
Veiklos sąnaudos yra 6695000000.000.
Koks yra įmonės grynųjų pinigų skaičius?
Įmonės grynieji pinigai yra 0.000.